Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Average Target Price of $67.50 According to Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $67.50.

A number of research analysts have recently commented on the company. B. Riley Financial restated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Canaccord Genuity Group upped their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. HC Wainwright increased their price objective on Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th.

Eton Pharmaceuticals Price Performance

ETON stock opened at $51.98 on Friday. Eton Pharmaceuticals has a 1 year low of $14.27 and a 1 year high of $66.37. The company has a market cap of $1.49 billion, a P/E ratio of 136.79 and a beta of 0.90. The firm has a 50-day moving average of $54.67 and a 200 day moving average of $38.80. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The business had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. On average, sell-side analysts forecast that Eton Pharmaceuticals will post 1.13 EPS for the current year.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the company’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the sale, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This represents a 45.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 16.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ETON. Hsbc Holdings PLC bought a new position in shares of Eton Pharmaceuticals in the second quarter worth approximately $1,531,000. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $1,232,000. Squarepoint Ops LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $2,156,000. Bank of New York Mellon Corp purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $4,281,000. Finally, Bank of Nova Scotia purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth approximately $623,000. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company’s strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton’s portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.